Canada's Green Light to Apotex's Ozempic Generic

The Canadian health regulator has approved Apotex's generic version of semaglutide, marking it as the second authorized generic version of Novo Nordisk's popular diabetes drug, Ozempic, in Canada.

The Canadian health regulator announced on Friday the approval of Apotex's generic semaglutide. This decision introduces the second authorized generic version of Novo Nordisk's successful diabetes medication, Ozempic, within Canada.

The original drug, developed by Danish pharmaceutical giant Novo Nordisk, has become a breakthrough treatment for individuals managing diabetes. Apotex, based in Canada, now joins the small group of manufacturers offering cost-effective alternatives.

This approval is expected to impact the Canadian diabetes patient community significantly by increasing access to essential treatment options while fostering market competition and potentially reducing medication costs.